18464846. COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)

COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY

Organization Name

Arizona Board of Regents on Behalf of Arizona State University

Inventor(s)

Shelley Haydel of Mesa AZ (US)

Christopher Diehnelt of Chandler AZ (US)

COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY - A simplified explanation of the abstract

This abstract first appeared for US patent application 18464846 titled 'COMPOSITIONS AND METHODS OF USE OF SYNTHETIC PEPTIDES WITH MYCOBACTERIUM ABSCESSUS INHIBITORY ACTIVITY

Simplified Explanation

The patent application discloses synthetic antimicrobial peptides, compositions comprising thereof, and methods of use for modulating symptoms of infections caused by mycobacteria or MRSA. Methods of identifying synthetic antimicrobial peptides against pathogens with no known effective treatment are also provided using a library of synthetic peptides.

• Synthetic antimicrobial peptides for modulating symptoms of infections caused by mycobacteria or MRSA
• Compositions comprising synthetic antimicrobial peptides
• Methods of identifying synthetic antimicrobial peptides against pathogens with no known effective treatment using a library of synthetic peptides

Potential Applications

The technology can be applied in the development of novel treatments for infections caused by mycobacteria or MRSA. It can also be used in the field of antimicrobial research to identify effective peptides against pathogens with no known treatment.

Problems Solved

This technology addresses the challenge of treating infections caused by mycobacteria or MRSA, which can be resistant to traditional antibiotics. It also provides a solution for identifying effective antimicrobial peptides against pathogens with no known treatment.

Benefits

The use of synthetic antimicrobial peptides offers a potential alternative to traditional antibiotics for treating infections. It provides a targeted approach to combating specific pathogens and can help in overcoming antibiotic resistance.

Potential Commercial Applications

The technology has potential commercial applications in the pharmaceutical industry for the development of new antimicrobial treatments. It can also be utilized in research institutions for the discovery of novel antimicrobial peptides.

Possible Prior Art

Prior art may include existing patents or research studies on synthetic antimicrobial peptides for treating infections caused by various pathogens. Studies on the efficacy of antimicrobial peptides against mycobacteria or MRSA could also be relevant.

How do synthetic antimicrobial peptides compare to traditional antibiotics in terms of efficacy and safety for treating infections caused by mycobacteria or MRSA?

Synthetic antimicrobial peptides offer a targeted approach to combating specific pathogens, potentially reducing the risk of resistance development. However, further studies are needed to compare their efficacy and safety with traditional antibiotics in clinical settings.

What are the potential challenges in scaling up the production of synthetic antimicrobial peptides for commercial use?

Scaling up production of synthetic antimicrobial peptides for commercial use may pose challenges in terms of cost-effectiveness, scalability, and regulatory approval. Research and development efforts are required to address these challenges and optimize the manufacturing process.

Original Abstract Submitted

Synthetic antimicrobial peptides, compositions comprising thereof, and methods of use for modulating one or more symptoms of an infection in a subject are disclosed. In some aspects, the infection is caused by mycobacteria, for example, a nontuberculous mycobacterium such as In other aspects, the infection is caused by or methicillin-resistant (MRSA). Also disclosed are methods of identifying synthetic antimicrobial peptides against a pathogen with no known effective treatment using a library of synthetic peptides.